Summary: A new immunotherapy treatment for ALS patients is not only safe, but can also help slow the progression of the disease, researchers report.
Source: Houston Methodist.
Recent research from Houston Methodist Hospital showed that a new immunotherapy was safe for patients with ALS and also revealed surprising results that could bring hope to patients who have this relentlessly progressive and fatal disease.
Amyotrophic lateral sclerosis, commonly known as ALS or Lou Gehrig’s disease, is a nervous system disorder in which nerve cells that control muscle movement degenerate, leading to weakness, speech and swallowing difficulties, impaired breathing, and ultimately death.
Researchers focused on regulatory T cells, also known as Tregs, which are immune cells that help protect the body from harmful inflammation that accelerates the progression of ALS.
Stanley H. Appel, M.D., neurologist and co-director of the Houston Methodist Neurological Institute, and his team launched a study to determine whether treatment with infusions of Tregs was safe and tolerable for ALS patients. This research will appear in the July 2018 issue of Neurology Neuroimmunology & Neuroinflammation.
“We found that many of our ALS patients not only had low levels of Tregs, but also that their Tregs were not functioning properly,” said Appel, senior author and chair of the department of neurology at Houston Methodist Hospital. “We believed that improving the number and function of Tregs in these patients would affect how their disease progressed.”
Appel and his team selected three patients at different stages of ALS progression for the study.
“As we believed, our results showed it was safe to increase their Treg levels,” Appel said. “What surprised us was that the progression of their ALS dramatically slowed while they received infusions of properly functioning Tregs. My hope is that this research changes ALS from a death sentence to a life sentence. It won’t cure a patient’s disease, but we can make a difference.”
The three patients in this study underwent leukapheresis, a procedure where blood is removed, white blood cells are separated from red blood cells, and red blood cells are returned to the body. Tregs were then separated from the white blood cells. Appel’s research team found Tregs that were not functioning properly in ALS patients returned to normal once outside of the body. They collaborated with M.D. Anderson Cancer Center’s Stem Cell Transplantation and Cellular Therapy program to increase the number of each patient’s own Tregs before administering them intravenously back into the patients.
“The goal of this study was to determine whether it is safe to increase the levels of functioning Tregs in ALS patients,” said Jason Thonhoff, M.D., Ph.D., Houston Methodist neurologist and lead author. “Larger studies will be required to determine whether it is an effective treatment, but as a clinician and researcher who specializes in ALS, I am very excited about the hope these initial findings provide.”
Each patient received eight Treg infusions during the study. The first four infusions were administered every two weeks, and the last four were administered once a month. Disease progression was measured using two ALS progression rating scales. Between the first round and second round of Treg infusions and then after the second round of infusions was completed, progression resumed within a few weeks to months following the last Treg infusion.
“A person has approximately 150 million Tregs circulating in their blood at any given time,” Thonhoff said. “Each dose of Tregs given to the patients in this study resulted in about a 30 to 40 percent increase over normal levels. Slowing of disease progression was observed during each round of four Treg infusions.”
Next, Appel and Thonhoff will launch a Phase 2 study to further evaluate the safety and effectiveness of Treg infusions in slowing the progression of ALS. They hope to turn this research into an off-the-shelf cellular therapy for ALS patients.
About this neuroscience research article
Funding: This research study was approved by the Food and Drug Administration and funded by the ALS Association and ALS Finding a Cure.
Source: Hannah Pietsch – Houston Methodist Publisher: Organized by NeuroscienceNews.com. Image Source: NeuroscienceNews.com image is in the public domain. Original Research: Open access research for “Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study” by Jason R. Thonhoff, David R. Beers, Weihua Zhao, Milvia Pleitez, Ericka P. Simpson, James D. Berry, Merit E. Cudkowicz and Stanley H. Appel in Nature Materials. Published May 18 2018. doi:10.1212/NXI.0000000000000465
Cite This NeuroscienceNews.com Article
[cbtabs][cbtab title=”MLA”]Houston Methodist “Immune Cells Hold Promise For Slowing ALS Progression.” NeuroscienceNews. NeuroscienceNews, 21 May 2018. <https://neurosciencenews.com/als-immune-cells-9097/>.[/cbtab][cbtab title=”APA”]Houston Methodist (2018, May 21). Immune Cells Hold Promise For Slowing ALS Progression. NeuroscienceNews. Retrieved May 21, 2018 from https://neurosciencenews.com/als-immune-cells-9097/[/cbtab][cbtab title=”Chicago”]Houston Methodist “Immune Cells Hold Promise For Slowing ALS Progression.” https://neurosciencenews.com/als-immune-cells-9097/ (accessed May 21, 2018).[/cbtab][/cbtabs]
Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study
Objective To determine whether autologous infusions of expanded regulatory T lymphoctyes (Tregs) into patients with amyotrophic lateral sclerosis (ALS) are safe and tolerable during early and later stages of disease.
Methods Three patients with ALS, with no family history of ALS, were selected based on their differing sites of disease onset and rates of progression. Patients underwent leukapheresis, and Tregs were subsequently isolated and expanded ex vivo. Tregs (1 × 106 cells/kg) were administered IV at early stages (4 doses over 2 months) and later stages (4 doses over 4 months) of disease. Concomitant interleukin-2 (2 × 105 IU/m2/injection) was administered subcutaneously 3 times weekly over the entire study period. Patients were closely monitored for adverse effects and changes in disease progression rates. Treg numbers and suppressive function were assayed during and following each round of Treg infusions. Results Infusions of Tregs were safe and well tolerated in all patients. Treg numbers and suppressive function increased after each infusion. The infusions slowed progression rates during early and later stages of disease. Spearman correlation analyses showed that increased Treg suppressive function correlated with slowing of disease progression per the Appel ALS scale for each patient: patient 1: ρ (rho) = −0.60, p = 0.003; patient 2: ρ = −0.71, p = 0.0026; and patient 3: ρ = −0.54, p = 0.016. Measures of maximal inspiratory pressure also stabilized, particularly in 2 patients, during Treg infusions.
Conclusions These results demonstrate the safety and potential benefit of expanded autologous Treg infusions, warranting further clinical trials in patients with ALS. The correlation between Treg suppressive function and disease progression underscores the significance of using Treg suppressive function as an indicator of clinical status.